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Abstract
Purpose:  In  multiple  myeloma,  skeletal  radiographs  are  still  regarded  as  the  reference  imaging
examination  because  they  help  to  establish  the  stage  of  the  disease  according  to  the  Durie-
Salmon Staging  System.  Whole-body  MRI  using  T1  and  STIR  sequences  increases  the  detection  of
myeloma  lesions.  MRI-measured  diffusion  has  demonstrated  high  sensitivity  in  terms  of  detec-
tion in  oncology.  The  main  objective  of  this  study  is  to  compare  conventional  radiographic
staging with  an  MRI  whole-body  diffusion  technique  (called  DWIBS)  in  detecting  bone  lesion
monoclonal  plasma  cell  pathologies  (multiple  myeloma,  plasma  cell  leukaemia,  plasmacytoma
and MGUS).
Materials  and  methods:  Twenty-seven  patients  were  included  (multiple  myeloma:  24;  plasma
cell leukaemia,  MGUS  and  plasmacytoma:  1  each).  All  of  them  had  a  whole-body  MRI  diffusion
examination  (using  a  DWIBS  sequence).  Diffusion  MRI  and  conventional  radiographs  were  com-
pared according  to  the  Durie-Salmon  Staging  System.  In  case  of  doubtful  lesions,  12  months  of
monitoring  was  used  as  the  reference  method  for  the  deﬁnitive  diagnosis.
Results:  The  overall  concordance  rate  between  the  two  techniques  was  63%.  The  DWIBS
sequence  detected  a  higher  number  of  lesions  leading  to  a  higher  Durie-Salmon  stage  in  37%
of the  patients:  one  stage  I  to  II,  seven  stage  I  to  III,  and  two  stage  II  to  III.  In  18.5%  of  the
patients,  the  MRI  was  positive  while  the  radiographs  were  normal  and  these  discrepancies  were
most often  located  in  sites  poorly  explored  by  X-ray  (spine,  pelvis  and  ribs).  In  one  patient
(4%), the  MRI  provided  a  stage  lower  than  that  of  the  X-rays  (stage  II  vs.  III).  In  this  case,  the
X-rays were  positive  at  the  humerus  and  femur,  unlike  the  DWIBS  sequence.  Our  per  site  analysis
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conﬁrmed  the  clear  superiority  of  the  DWIBS  sequence  when  compared  with  X-rays  in  the  explo-
ration of  the  cervical  spine  (56  vs.  0%,  P  <  0.001),  dorsal  spine  (81vs.  31%,P  <  0.0002),  lumbar
spine (70  vs.  35%,  P  <  0.0124),  pelvis  (81  vs.  33%,  P  <  0.0005)  and  ribs  (74  vs.  36%,  P  <  0.0009).
Conclusion:  The  DWIBS  MRI  leads  to  an  increase  in  the  ﬁnal  Durie-Salmon  stage.  Although  its
place in  the  preoperative  treatment  of  multiple  myeloma  still  has  to  be  assessed,  this  study
suggests its  potential  interest.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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Xultiple  myeloma  (MM)  is  a  malignant  lymphoid  haemato-
ogical  malignancy  of  B  cells  characterised  by  proliferation,
ithin  the  bone,  of  a  plasma  cell  clone  that  synthesises  a
onoclonal  immunoglobulin.  It  accounts  for  about  1%  of  all
ancers  and  10%  of  all  malignant  haematological  diseases.
he  incidence  increases  with  age  with  a  peak  at  the  age  of
0  years  [1,2].
It  is  characterised  by  its  medullary  osseous  tropism,  the
rigin  of  major  morbid-mortality.  Up  to  90%  of  the  patients
evelop  osteolytic  lesions  during  the  disease  and  about  60%
f  them  present  a  pathological  fracture  [2].
The  detection  of  these  lesions  is  capital  in  the  staging,
valuation  of  the  treatment  and  prognosis.
X-rays  of  the  skeleton  are  still  considered  to  be  the  gold
tandard  in  spite  of  a  great  many  limitations.  In  particular,
hey  only  detect  lytic  lesions  after  the  loss  of  over  30%  of
he  bone  mineral  density,  they  poorly  visualise  certain  zones
nd  they  do  not  detect  diffuse  medullary  invasion  [2].
As  of  2006,  whole-body  magnetic  resonance  imaging
MRI)  has  proven  its  superiority  over  the  conventional  radio-
ogical  assessment.  STIR  and  T1  MRI  sequences  are  used
3—5].  Based  on  these  studies,  in  2009,  the  consensus  con-
erence  of  the  International  myeloma  working  group  [6]  gave
 new  place  to  the  MRI,  recognising  its  value  as  a comple-
ent  to  X-rays  of  the  skeleton,  in  particular  if  they  are
ormal.  This  conference  also  recommended  the  MRI  of  the
pine  in  addition  to  the  X-rays  for  the  staging  of  a  plasmacy-
oma.  Finally,  in  case  of  progression,  the  MRI  should  be  used
f  the  X-rays  are  normal.  As  of  2010,  whole-body  diffusion
as  demonstrated  its  value  in  myeloma  [7—10].  Neverthe-
ess,  as  far  as  we  are  aware,  a  study  has  not  been  carried  out
omparing  whole-body  diffusion  MRI  and  the  conventional
adiological  assessment.
The  main  goal  of  this  study  is  to  assess  the  value  of
hole-body  diffusion  imaging  (called  ‘‘diffusion-weighted
maging  with  background  body  signal  suppression’’  [DWIBS]
y  Philips)  in  the  detection  of  bone  lesions  in  patients  suf-
ering  from  monoclonal  plasma  cell  pathologies  (myeloma,
lasma  cell  leukaemia,  plasmacytoma,  monoclonal  gamma-
athy  of  undetermined  signiﬁcance  [MGUS]),  compared  with
-rays  of  the  skeleton.
aterials and methods
atientsll  of  the  patients  presenting  a  monoclonal  plasma  cell  dis-
rder  (myeloma,  plasma  cell  leukaemia,  plasmocytoma  and
GUS)  between  30  January  2009  and  12  October  2010  at  the
A
t
lheumatology,  haematology  and  internal  medicine  depart-
ents  of  CHU  de  Poitiers  were  incurable.  Their  signed,
nformed  consent  was  obtained.  Patients  presenting  another
on-cured  neoplasm  that  may  have  been  the  origin  of  the
econdary  bone  lesions,  those  where  the  time  between  the
-rays  and  the  DWIBS  exceeded  1.5  months  and  those  receiv-
ng  chemotherapy  between  the  two  examinations  were
xcluded.
The  following  data:  age,  type  of  plasma  cell  disease,  type
f  monoclonal  protein  and  status  during  the  examinations
as  collected.
maging
iffusion-weighted  imaging  with  background  body
ignal  suppression  (DWIBS)  sequence  magnetic
esonance  imaging  (MRI)
ll  of  the  examinations  were  carried  out  on  a  1.5  Tesla
RI  (Intera®),  Philips,  Best,  Netherlands.  The  protocol
ncluded:  ﬁrstly,  T1  sagittal  sequences  T1  (Repetition  Time
RT]  =  400  ms,  Echo  Time  =  10  ms,  matrix,  number  of  excited
tates:  4,  4  mm  thick  sections,  intergap  of  0.4  mm,  ﬁeld  of
iew  of  370  mm)  and  STIR  (RT  =  2500  ms,  ET  =  60  ms,  inver-
ion  time  [IT]  =  170  ms,  matrix,  number  of  excited  states,
 mm  thick  sections,  intergap  of  0.4  mm,  ﬁeld  of  view  of
70  ms)  on  the  whole  spine;  secondly,  a  DWIBS  sequence:
T  5834  ms/ET  72  ms/TI  180  ms,  FOV  460  mm,  matrix  128,
 = 1000s/mm2. This  acquisition  was  obtained  from  the  ver-
ex  to  the  top  of  the  thighs,  with  free  breathing,  a  shift  of
he  automatic  table,  a type  ‘‘Q  body’’  body  antenna  and  six
lements.  Three  levels  of  80  axial  sections  in  4  mm  isotropic
oxels  (vertex  to  the  aortic  arch,  aortic  arch  to  the  lower
ole  of  the  kidneys  and  lower  poles  of  the  kidneys  to  the
op  of  the  thighs)  were  obtained.  The  acquisition  took  about
2  minutes.
The  images  were  analysed  in  inverted  greyscale  to  obtain
maging  close  to  that  of  position  emission  tomography.  The
mages  obtained  were  presented  with  the  two  b  weightings
sed:  b0  (image  in  T2  weighting)  and  b  =  1000  (diffusion-
eighted  image).  The  images  could  beneﬁt  from  3D  multi-
lanar  reconstructions  (MPR)  enabling  analysis  in  the  three
lanes  or  maximum  intensity  projection  (MIP)  reformatting,
or  an  easy  and  fast  reading  of  the  examination.
-rays  of  the  skeleton
ll  patients  beneﬁted  from  front  and  lateral  X-rays  of
he  head,  front  humerus,  front  and  lateral  cervical-dorsal-
umbar  vertebrae,  front  femurs  and  front  ribs.
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Analysis  of  the  bone  lesions
The  examinations  were  read  on  PACS  console  with  consen-
sus  between  a  senior  and  a  junior  radiologist.  They  were
informed  of  the  age  and  sex  of  the  patient  but  not  the  type
of  monoclonal  plasma  cell  disorder.
The  DWIBS  images  were  visualised  in  inverted  greyscale.
The  window  function  was  adapted  in  order  to  obtain  a  max-
imum  attenuation  of  the  background  noise  by  maintaining  a
signal  for  the  vertebral  body  on  the  weighted  b1000  images.
The  reading  began  with  a  global  analysis  on  the  three  series
of  weighted  b1000  coronal  MIP  sections  and  then  an  analysis
was  carried  out  on  the  weighted  b1000  native  axial  sections
using  weighted  b0  sections  for  the  anatomical  registration.
Deﬁnition  of  the  myeloma  lesions:  on  the  X-rays,  a
rounded  or  oval  non-surrounded  gap  (gap  Ib  or  Ic  in  the
Lodwick  classiﬁcation)  was  considered  to  be  a  myelomatous
lesion.  The  presence  of  vertebral  fractures  was  noted.
The  MRI  analysis  involved  two  steps:  on  the  T1  and
STIR  imaging,  a  nodular  image  in  STIR  hyper  signal,  T1
hypo-signal,  a  ‘‘salt  and  pepper’’  appearance,  a  global  hypo-
signal  (higher  than  the  inter-vertebral  disk)  were  considered
to  be  pathological.  The  presence  of  vertebral  fractures,
epiduritis  or  extra-medullary  impairment  was  also  noted.
The  interpretation  of  the  diffusion  sequences  was  only
qualitative:  a  lesion  presenting  a  diffusion  restriction,
whether  nodular  or  more  diffuse  was  considered  to  be  a
myelomatous  impairment.  The  lymph  nodes,  spleen,  genital
organs,  central  nervous  system  spontaneously  presenting  a
restriction  of  diffusion  were  not  analysed.  Each  suspicious
image  on  the  b1000  image  was  compared  with  the  b0  dif-
fusion  image  and  the  T1  and  STIR  sequences  to  verify  the
location.  The  radiologists  then  rated  each  lesion  as  either
absent,  present  or  doubtful.
On  the  basis  of  the  framework  described  above,  each
patient  was  rated  according  to  the  Durie-Salmon  PLUS  stag-
ing  system  (SD  PLUS)  [2,11,12]:
• stage  1  (from  0  to  4  focal  lesions  or  mild  medullary  inﬁl-
tration);
• stage  2  (5  to  20  focal  lesions  or  moderate  medullary  inﬁl-
tration);
• stage  3  (over  20  focal  lesions  or  severe  medullary  inﬁltra-
tion).
All  patients  had  6  months  of  clinical  and  biological  moni-
toring  in  order  to  eliminate  the  possibility  of  a  false  positive
in  the  diffusion  MRI  (another  cancer,  inﬂammation  or  hae-
morrhage)  or  in  case  of  doubtful  lesions  in  the  conventional
X-rays.  This  monitoring  was  considered  to  be  the  reference
method  in  case  of  disagreement.
Statistics
Descriptive  analyses
The  qualitative  variables  are  described  by  their  number
and  percentage,  the  quantitative  variables  by  their  mean,
median  and  extreme  value.Comparative  analyses
The  overall  concordance  between  the  two  techniques  was
studied.  Identical  results  obtained  with  the  DWIBS  MRI  and
s
•
•
•631
he  X-rays  were  deﬁned  as  ‘‘concordant’’.  Those  differing
ere  deﬁned  as  ‘‘discordant’’.
McNemar’s  test  was  used  to  compare  the  proportion  of
ositivity  of  the  two  techniques  according  to  the  different
ites.
A  P  value  under  0.05  was  considered  to  be  signiﬁcant  for
he  comparative  analyses.
esults
opulation
hirty-two  patients  suffering  from  monoclonal  plasma  cell
isease  were  included.  Five  of  them  were  secondarily
xcluded:  the  time  between  the  X-rays  and  the  MRI
xceeded  1.5  months  for  four  patients  and  one  patient
eceived  two  chemotherapies  between  the  two  examina-
ions.  Twenty-seven  patients  including  14  women  and  13
en  were  ﬁnally  included.  The  age  of  the  patients  ranged
rom  38  to  87  years  with  a  mean  of  71  years  and  a  median
f  74  years.  The  series  included  24  cases  of  myeloma,  one
ase  of  plasma  cell  leukaemia,  one  MGUS  and  one  plasma-
ytoma.  Fourteen  patients  had  a  newly  diagnosed  MM,  ﬁve
 recurrence  of  MM,  ﬁve  a  known  MM,  one  a  recurrence  of
lasma  cell  leukaemia,  one  newly  diagnosed  MGUS  and  one
ecurrence  of  plasmocytoma  in  a  radiotreated  zone.
Table  1  describes  the  patient  characteristics.
The  mean  time  between  the  X-rays  and  the  MRI  was  15
ays  (median  time  of  8  days,  extreme  values  between  0  and
 month  10  days).
keletal X-rays
wo  hundred  and  ﬁfty-nine  sites  were  analysed:  24  skulls,  23
ervical  vertebrae,  26  dorsal  vertebrae,  26  lumbar  verte-
rae,  54  humerus,  27  pelvises,  54  femurs  and  25  ribs.
he  incomplete  conventional  radiological  assessments  were
aved  for  the  correlation  between  the  MRI  and  radio-
raphic  classiﬁcation  because  the  number  of  lesions  in  these
atients  exceeded  20  in  the  assessment  (automatically  clas-
ifying  these  patients  at  stage  III  of  the  DS  Plus).
The  X-rays  were  positive  (that  is,  at  least  1  lesion)  in  17
f  the  27  patients  (63%),  negative  in  eight  patients  (30%),
nd  doubtful  in  two  patients  (7%).  These  two  patients  pre-
ented  isolated  vertebral  fractures  (2  and  3  fractures).  They
ere  included  in  the  overall  results  because  the  number  of
oubtful  lesions  was  under  5,  thereby  not  modifying  the
tage  (stage  I):  in  one  patient,  the  X-rays  revealed  three
ractures  from  L3  to  L5;  in  the  other  patient,  they  revealed
wo  fractures  of  T6  and  T8.  In  the  ﬁrst  patient,  the  location
f  the  myeloma  was  retained  in  view  of  the  clinical  and  bio-
ogical  monitoring.  In  the  second  patient,  the  compression
as  attributed  to  osteoporosis  (past  history  of  osteoporosis
elated  to  long-term  cortisone  treatment  for  Crohn’s  dis-
ase,  spontaneous  improvement  in  the  pain  and  stability  of
he  gamma  globulin  peak).
Concerning  the  distribution  of  the  different  anatomical
ites,  the  X-rays  were  positive  in  the:
skull  in  37.5%  of  the  patients  (9  patients  out  of  24);
humerus  in  48%  (13  patients  out  of  27);
pelvis  in  33%  (9/27);
632  S. Narquin  et  al.
Table  1  Characteristics  of  the  patients  in  the  study.
Patient  Age/sex  MM  Status
1  48/M  IgG  Gammapathic  progression  in  MM
2  73/M  IgG  MM  in  therapeutic  abstention  but  in  recurrence
3  81/F  MGUS  at  IgA  Diagnosis  MGUS
4  73/F  IgG  Diagnosis  MM
5  86/F  IgG  and  IgA  MM  in  recurrence  from  stage  I  to  II  of  DS
6  69/F CL  Diagnosis  MM
7  79/M CL  Diagnosis  MM
8  77/M IgG  Diagnosis  MM
9  79/F  IgG  Diagnosis  MM
10  64/F  IgG  MM  known
11  61/F  IgG  MM  in  full  response
12  76/M  IgG  MM  in  recurrence
13  79/M  CL  Diagnosis  MM
14  84/M  IgG  MM  in  recurrence
15  62/F  IgGk  MM  known
16  38/M  plasmC  NS  Plasmocytoma  recurrence  in  RT  zone
17  77/M  MIgK  then  leuk  at  P  Plasma  cell  leukaemia  in  recurrence
18  52/F  IgA  MM  known
19  54/M  IgA  Diagnostic  MM
20  87/M  IgA  Diagnostic  MM
21  84/M  IgA  Progression  monoclonal  gammopathy  in  MM
22  76/M  IgA  Diagnosis  MM
23  54/F  IgA  MM  known
24  74/M  IgG  Diagnosis  MM
25  82/F  IgG  MM  recurrence
26  74/F  IgA  Diagnosis  MM
27  64/F  CL  Diagnosis  MM
MM: multiple myeloma.
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•femurs  in  41%  (11/27);
ribs  in  36%  (9/25);
cervical  vertebrae  in  0%  (0/23);
dorsal  vertebrae  in  31%  (8/26);
lumbar  vertebrae  in  35%  (9/26).
agnetic resonance imaging
MRI)-diffusion-weighted imaging with
ackground body signal suppression (DWIBS)
wo  hundred  and  sixty-one  sites  were  analysed:  27  skulls,  27
ervical  vertebrae,  27  dorsal  vertebrae,  27  lumbar  verte-
rae,  54  humerus,  26  pelvises,  46  femurs,  27  ribs.  The
resence  of  a  full  hip  replacement  generated  artefacts  that
revented  the  analysis  of  eight  femurs  and  one  pelvis.
The  DWIBS  MRI  was  positive  (that  is,  at  least  1  lesion)  in
2  patients  (81%)  and  negative  in  ﬁve  patients  (19%).
Concerning  the  different  anatomical  sites,  the  DWIBS
equence  was  positive  in  the:
skull  in  15%  of  the  patients  (4  patients  out  of  27);
humerus  in  33%  (9  patients  out  of  27);
pelvis  in  81%  (21/26);
femurs  in  27%  (6/22);
ribs  in  74%  (20/27);
cervical  vertebrae  in  56%  (15/27);
dorsal  vertebrae  in  81%  (22/27);
•lumbar  vertebrae  in  70%  (19/27).
Figs.  1-3  illustrate  the  results.
None  of  the  patients  presented  epiduritis  in  the  T1  and
TIR  sequences.
omparison of the skeletal X-rays and the
iffusion-weighted imaging with background
ody signal suppression (DWIBS)
atient  by  patient  analysis
mong  the  27  patients,  17  presented  the  same  stage  of  DS
lus,  an  overall  rate  of  concordance  of  63%.  In  three  cases
ut  of  27  (11%),  the  X-rays  and  DWIBS  were  negative.
The  DWIBS  revealed  a  higher  number  of  lesions  leading
o  an  increase  in  the  stage  in  10  patients  (37%):  one  from
tage  I to  II,  seven  from  stage  I  to  III,  and  two  from  stage  II
o  III:
one patient  had  negative  X-rays  (stage  I)  and  one  stage  II
in  DWIBS  (13  vertebral);
three  patients  had  negative  X-rays  (stage  I)  and  over  20
lesions  in  DWIBS  (2  in  the  vertebrae,  pelvis  and  ribs,  1  in
all  of  the  sites  except  the  skull);
four  patients  had  at  least  ﬁve  lesions  in  the  X-rays  (stage
I)  and  one  stage  III  in  DWIBS  (in  2  patients:  DWIBS  anoma-
lies  in  the  humerus,  vertebrae,  pelvis  and  ribs  versus  1
Whole-body  diffusion  MRI  and  X-rays  in  myeloma  633
Figure 1. Multiple myeloma Durie-Salmon stage III: on the magnetic resonance imaging (MRI)-diffusion-weighted imaging with background
body signal suppression (DWIBS) (a), over 20 focal lesions are visible; L5, pelvis, ribs, diffuse dorso-lumban spinal inﬁltration and two  left
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Slatero-thoracic masses (pleural plasmocytomas); in the radiological
the upper plateau of L5 and iliac wing gaps and ilio-pubic branches
rib  lesion  in  the  X-rays  for  one  and  4  lesions  in  the  verte-
brae,  pelvis,  ribs  and  clavicle  for  the  other;  in  2  patients:
DWIBS  anomalies  in  the  vertebrae,  pelvis  and  ribs  versus
3  vertebral  fractures  in  the  X-rays  for  one  of  them  and  3
humeral  and  vertebral  lesions  for  the  other);
• two  patients  had  a  stage  II  in  the  X-rays  and  III  in  DWIBS
(in  1  patient:  DWIBS  anomalies  in  the  vertebrae,  pelvis
and  ribs  versus  8  lesions  in  the  humerus  and  vertebrae  in
the  X-rays;  in  the  other  patient:  DWIBS  anomalies  in  all
sites  except  for  the  skull  versus  5  lesions  in  the  humerus,
vertebrae  and  pelvis  on  the  X-rays).
In  ﬁve  cases  (18.5%  of  the  patients),  the  DWIBS  was  posi-
tive  while  the  X-rays  were  normal,  leading  to  an  increase  in
stage  in  4  of  them  (1  with  a  stage  II  in  DWIBS  and  3  with  a
stage  III  in  DWIBS,  as  indicated  in  the  previous  paragraph).
The  last  patient  had  a  stage  I  in  DWIBS  (4  lesions  in  the  dorsal
and  lumbar  vertebrae  and  pelvis).
T
•ssment: presence of two left latero-thoracic masses, a fracture of
ough less numerous than on the MRI (b—d).
The  DWIBS  sequence  revealed  a  smaller  number  of  lesions
eading  to  a  lower  stage  in  one  patient  (4%):  stage  III  on  the
-rays  and  II  in  DWIBS:  the  X-rays  detected  suspect  lesions
n  all  of  the  sites  except  for  the  cervical  vertebrae,  while
he  DWIBS  sequence  was  positive  at  the  skull,  the  dorsal
ertebrae,  the  pelvis  and  the  ribs  but  not  at  the  humerus
nd  femurs  as  opposed  to  the  X-rays.
In  one  case,  the  X-rays  detected  a  suspect  lesion  in  the
eft  acromion  while  the  DWIBS  sequence  was  normal.
The  radiographic  assessment  and  whole-body  MRI  in  the
wo  patients  presenting  a  MGUS  and  a  plasmacytoma  were
ormal.
ite-by-site  analysis
he  DWIBS  sequence  was  most  often  positive  in  the:
cervical  vertebrae:  56%  of  the  patients  versus  0%  in  radio-
graphy  (P  <  0.001);
634  
Figure 2. Multiple myeloma stage I according to the initial
osseous assessment (no anomaly). On the magnetic resonance imag-
ing (MRI)-diffusion-weighted imaging with background body signal
suppression (DWIBS), over 20 lesions are visible with a severe dif-
fuse myelematous inﬁltration at the spine and pelvis and moderate
at several ribs.
Figure 3. Diagnosis multiple myeloma stage II. X-rays: no gap
and presence of three fractures of the upper plateaux from L3 to
L5. On the diffusion-weighted imaging with background body signal
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MRI  detected  an  inﬁltration  of  the  bone  marrow  while  theuppression (DWIBS) imaging, over 20 lesions with severe diffuse
yelomatous inﬁltration are visible (arrows).
dorsal  vertebra:  81  %  versus  31  %  (P  =  0.0003);
lumbar  vertebrae:  69  %  versus  35  %  (P  =  0.0201);
pelvis:  81  %  versus  34  %  (P  =  0.0005);
ribs:  72  %  versus  36  %  (P  =  0.0027).
The  DWIBS  sequence  was  less  often  positive  in  the:
X
m
bS. Narquin  et  al.
skull:  16%  of  the  patients  versus  36%  in  radiography
(P  =  0.0253);
humerus:  33%  versus  48%:  difference  not  signiﬁcant
(P  =  0.2482);
femurs:  27%  versus  41%:  difference  not  signiﬁcant
(P  =  0.1797).
iscussion
-rays  of  the  skeleton  remain  the  reference  imaging  exami-
ation  and  should  be  systematically  carried  out  for  the  initial
taging  and  monitoring  of  patients  with  multiple  myeloma.
evertheless,  this  study  demonstrates  that  this  assessment
s  insufﬁcient  since  it  seems  to  minimise  the  myelomatous
mpairment  in  37%  of  the  cases  compared  with  the  diffusion
RI.  As  far  as  we  are  aware,  it  consists  of  the  ﬁrst  study  to
emonstrate  this  superiority.
Other  studies  have  already  demonstrated  the  limitations
f  the  conventional  radiological  assessment  in  terms  of
ensitivity  with  respect  to  the  TEP-CT  and  especially  with
espect  to  the  MRI  [3—5,13,14].  This  is  why  Durie  et  al.
11]  recommended  integrating  the  pelvic-spinal  MRI  in  the
nitial  assessment  for  MM  patients,  in  the  Durie-Salmon
lus  staging.  In  fact,  this  examination  helps  better  grade
he  bone  extension,  class  little  or  non-secreting  myelo-
as  and  attribute  an  unfavourable  prognosis  to  patients
ith  over  20  focal  lesions  and/or  extra-medullary  impair-
ent.
However,  several  studies  have  shown  false  negatives  in
he  pelvic-spinal  MRI  that  does  not  explore  the  appendicular
egions.  In  the  study  by  Walker  et  al.  [13], 16%  of  the  focal
esions  were  located  outside  of  the  axial  skeleton.  According
o  Lecouvet  et  al.  [15], the  replacement  of  the  skeletal  X-
ays  by  a  pelvic-spinal  MRI  resulted  in  an  underestimate  of
he  stage  in  almost  10%  of  the  patients.
This  problem  was  in  part  resolved  with  the  development
f  the  whole-body  MRI.  Several  studies  have  demonstrated
he  superiority  of  this  technique  over  X-rays  in  monoclonal
lasma  cell  diseases,  although  they  rely  on  T1  and  STIR
equences  and  do  not  associate  diffusion  [3—5].
However,  the  diffusion-weighted  MRI  sequence  is  very
ensitive  imaging  in  terms  of  the  detection  of  hypercellular
esions  [7,9,16].
Our  study  seems  in  favour  of  the  superiority  of  the  MRI,
n  particular  the  diffusion-weighted  DWIBS  sequence  over
keleton  X-rays.  According  to  the  Durie-Salmon  Plus,  the
WIBS  sequence  grades  37.5%  of  the  patients  at  a  higher
tage.  In  18.5%  of  the  patients,  the  DWIBS  sequence  was
ositive  while  the  X-rays  were  normal.  This  is  probably  due
o  the  limits  of  the  conventional  X-ray  in  the  spine,  the
elvis  or  the  ribs,  zones  that  are  difﬁcult  to  explore  with
his  technique.
These  results  support  those  in  the  literature,  even  if
revious  MRI  studies  did  not  involve  the  same  whole-body
iffusion  technique.  In  the  study  by  Dinter  et  al.  [5],  the
hole-body  MRI  graded  19/60  patients  (32%)  at  a  higher  DS
lus  stage.  In  that  of  Ghanem  et  al.  [3],  the  whole-body-rays  were  negative  in  10/54  patients  (19%)  and  detected
ore  extensive  anomalies  in  27  of  the  30  patients  (90%)  with
one  disease.
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In  the  study  by  Walker  et  al.  [13]  on  611  patients  treated
by  autolog  transplant,  52%  of  the  267  patients  with  normal
X-rays  presented  focal  lesions  in  the  MRI.  In  particular,  a
signiﬁcantly  higher  proportion  of  patients  presented  lesions
of  the  vertebra,  pelvis  and  sternum.  The  percentages  were
similar  in  the  skull  and  the  shoulders  and  lower  in  the  ribs
and  long  bones.
Our  site-by-site  analysis  conﬁrms  the  distinct  superiority
of  the  DWIBS  sequence  over  the  X-rays  in  the  exploration  of
the  spine,  the  pelvis  and  the  ribs.  This  supports  the  Walker
study  [13].  The  non-visible  or  poorly  visible  costal  medullary
inﬁltrations  in  T1,  difﬁcult  to  interpret  in  STIR,  appear  much
more  evident  in  coronal  diffusion  [17].
In  one  patient  (4%),  the  DWIBS  sequence  provided  a  lower
stage  than  that  of  the  X-rays  (stage  II  vs.  III).  As  regards  the
location,  the  skull,  femur  and  humerus  were  the  most  dis-
cordant  regions  even  though  the  results  are  not  statistically
signiﬁcant  for  the  last  two  sites.  These  results  are  more  or
less  concordant  with  those  of  the  study  by  Walker  et  al.  [13]
as  regards  the  humerus  and  femurs.  However,  our  results  are
discordant  in  the  skull  since  Walker  et  al.  [13]  found  simi-
lar  results  with  both  techniques.  In  the  study  by  Ghanem
[3],  the  MRI  was  even  higher  than  the  X-rays  with  at  least
one  cranial  lesion  detected  in  21/30  patients  (70%)  versus
16/30  (53%)  in  the  X-rays.  The  relatively  low  performance
of  the  diffusion-weighted  sequence  on  the  skull  is  difﬁcult  to
account  for  and  therefore  has  to  be  conﬁrmed  with  a  larger
series.
Only  visual  analysis  seemed  sufﬁcient:  the  value  of
the  calculation  of  the  apparent  coefﬁcient  of  diffusion
(ACD)  seems  limited  since  the  values  cannot  be  reproduced
from  one  machine  to  another,  vary  in  the  same  patient
by  at  least  14%  in  the  time  and  this  measure  renders
the  reading  more  complex.  In  addition,  its  pertinence  in
distinguishing  malignant  and  benign  tissue  remains  debat-
able.  Nevertheless,  this  measure  may  be  of  value  in  the
monitoring  of  plasma  cell  lesions  under  treatment  as  this
seems  to  have  been  demonstrated  in  other  cancerous  lesions
[16].
This  study  has  several  limitations:
• the  size  of  the  population  remains  limited  and,  in  addi-
tion,  it  is  heterogeneous  including  different  forms  of
plasma  cell  disease.  Nevertheless,  the  study  only  involved
tumour  detection  and,  for  this  reason,  it  is  interesting
to  include  patients  presenting  a  lesion  (plasmacytoma)
or  patients  without  a  focal  lesion  (MGUS).  This  study
emphasises  the  value  of  diffusion  since,  in  the  case  of
these  lesions,  the  major  problem  is  the  existence  of
occult  bone  lesions  transforming  the  diagnosis  into  a
true  myeloma.  Finally,  it  should  be  noted  that  this  is
a  preliminary  study  and  has  to  be  conﬁrmed  by  larger
series;
• several  patients  beneﬁted  from  chemotherapy  between
the  MRI  and  the  radiographic  assessment.  We  considered
that  the  time  (1  month)  was  too  short  to  modify  the  imag-
ing  but  this  has  to  be  assessed  in  a  future  study;
• the  X-rays  and  MRI  were  again  examined  by  two  radio-
logists  in  consensus  and  the  inter-  and  intra-observer
variability  in  the  reading  of  the  MRI  still  has  to  be
assessed;
• this  study  does  not  present  a  ‘‘gold  standard’’.  Obviously,
a  histological  conﬁrmation  is  impossible  in  practice  since635
a biopsy  of  all  of  the  suspect  lesions  in  a  patient  is  not
ethical.  The  divergences  between  the  two  techniques
are  therefore  difﬁcult  to  interpret  since  it  may  involve
a  false  negative  in  one  examination  or  a  false  negative  in
the  other.  In  this  study,  we  considered  that  bone  anoma-
lies  visible  in  DWIBS  were  a  priori  myeloma  lesions  and
confronted  this  diagnosis  with  the  clinical-biological  mon-
itoring,  this  being  considered  as  the  reference  method  in
case  of  doubt.  The  causes  of  false  diffusion-weighted  posi-
tives  (inﬂammation,  bleeding,  other  malignant  lesions)
were  thereby  excluded;
the  protocol  included,  as  stipulated  in  the  recommenda-
tions,  imaging  of  the  spine  and  pelvis  (T1  and  STIR)  and
therefore  did  not  include  the  upper  limbs  or  the  entire
lower  limbs.  The  overall  comparison  of  the  number  of
lesions  detected  by  the  ‘‘conventional’’  sequences  and
the  diffusion-weighting  was  not  carried  out.  This  compar-
ison  has  already  been  carried  out,  demonstrating  that  10%
of  the  lesions  were  missed  with  only  these  conventional
sequences.  Moreover,  this  question  was  not  the  purpose
of  this  study;
ﬁnally,  we  still  do  not  have  any  data  on  the  prognostic
impact  of  the  additional  lesions  described  in  MRI.  The
patients  were  treated  on  the  basis  of  the  radiological
assessment  and  not  the  results  of  the  diffusion-weighted
MRI  as  this  was  considered  to  be  non-validated.  A  future
study  should  assess  the  prognostic  value  of  diffusion-
weighted  MRI.
onclusion
he  whole-body  diffusion-weighted  MRI  (DWIBS),  detects  a
igher  number  of  lesions  inducing  an  increase  in  the  Durie-
almon  Plus  stage  in  over  a  third  of  the  patients.  This
echnique  seems  of  particular  use  in  anatomical  zones  that
re  difﬁcult  to  explore  with  conventional  radiography  (ribs,
elvis  and  spine).
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